- Home
- TCPC vs AUTL Comparison
TCPC vs AUTL Comparison
Compare TCPC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCPC
- AUTL
- Stock Information
- Founded
- TCPC 2006
- AUTL 2014
- Country
- TCPC United States
- AUTL United Kingdom
- Employees
- TCPC N/A
- AUTL N/A
- Industry
- TCPC Finance/Investors Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCPC Finance
- AUTL Health Care
- Exchange
- TCPC Nasdaq
- AUTL Nasdaq
- Market Cap
- TCPC 665.8M
- AUTL 625.4M
- IPO Year
- TCPC 2012
- AUTL 2018
- Fundamental
- Price
- TCPC $7.81
- AUTL $2.63
- Analyst Decision
- TCPC Hold
- AUTL Strong Buy
- Analyst Count
- TCPC 4
- AUTL 5
- Target Price
- TCPC $7.50
- AUTL $9.32
- AVG Volume (30 Days)
- TCPC 475.0K
- AUTL 1.7M
- Earning Date
- TCPC 08-06-2025
- AUTL 08-07-2025
- Dividend Yield
- TCPC 15.09%
- AUTL N/A
- EPS Growth
- TCPC N/A
- AUTL N/A
- EPS
- TCPC N/A
- AUTL N/A
- Revenue
- TCPC $259,596,996.00
- AUTL $9,011,000.00
- Revenue This Year
- TCPC N/A
- AUTL $461.76
- Revenue Next Year
- TCPC N/A
- AUTL $112.66
- P/E Ratio
- TCPC N/A
- AUTL N/A
- Revenue Growth
- TCPC 20.88
- AUTL N/A
- 52 Week Low
- TCPC $6.27
- AUTL $1.11
- 52 Week High
- TCPC $11.03
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TCPC 55.20
- AUTL 69.63
- Support Level
- TCPC $7.66
- AUTL $2.40
- Resistance Level
- TCPC $7.92
- AUTL $2.52
- Average True Range (ATR)
- TCPC 0.14
- AUTL 0.11
- MACD
- TCPC 0.02
- AUTL -0.00
- Stochastic Oscillator
- TCPC 78.85
- AUTL 85.97
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.